1. The role of immunotherapy in relapse/refractory precursor‐B acute lymphoblastic leukaemia: real‐life UK/Ireland experience in children and young adults.
- Author
-
Ottaviano, Giorgio, Baird, Susan, Bonney, Denise, Connor, Philip, Cummins, Michelle, Evans, Pamela, Gibson, Brenda, Hough, Rachel, Ingham, Danielle, Kelly, Anne, Qureshi, Amrana, Lancaster, Donna, Moppett, John, Norton, Alice, Payne, Jeanette, Stockley, Simone, Ghorashian, Sara, Amrolia, Persis, Qasim, Waseem, and Vora, Ajay
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *YOUNG adults , *IMMUNOTHERAPY , *CYTOKINE release syndrome - Abstract
Treatment of relapsed/refractory B-precursor acute lymphoblastic leukaemia (R/R B-ALL) in children remains a challenge, with only 30-50% of patients being salvaged by intensive chemotherapy and allogeneic haematopoietic stem cell transplantation (HSCT),1 with a dismal survival for those who relapse after HSCT.2 Results of immunotherapy with blinatumomab or autologous/allogeneic chimeric antigen receptor (CAR)-T cells hold out a promise of better outcomes3-6 and are now moving to the front-line of treatment protocols for selected high-risk patients (AALL1721/CASSIOPEIA, NCT03876769). The panel database included 230 patients with B-ALL, and for 138 patients (60%) the referring centre sought advice on curative treatment. The panel recommended antibody therapy for 47 patients (34%): blinatumomab for 34 patients, inotuzumab for eight, either blinatumomab or inotuzumab for five. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF